Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aberrant epigenome in -derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Torrent, Roger
  • Richaud, Yvonne
  • Sánchez-Danés, Adriana
  • Vilarrasa-Blasi, Roser
  • Sánchez, Alex|||0000-0002-8673-7737
  • Mosquera, José Luis|||0000-0002-7852-4993
  • Soriano, Jordi
  • López-Barneo, José
  • Canals, Josep M.|||0000-0001-6829-7670
  • Alberch i Vié, Jordi|||0000-0002-8684-2721
  • Raya, Ángel|||0000-0003-2189-9775
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Consiglio, Antonella
  • Martín-Subero, José I.
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Tolosa, Eduardo
The epigenomic landscape of Parkinson's disease () remains unknown. We performed a genomewide methylation and a transcriptome studies in induced pluripotent stem cell ()-derived dopaminergic neurons (n) generated by cell reprogramming of somatic skin cells from patients with monogenic 2-associated (L2) or sporadic (), and healthy subjects. We observed extensive methylation changes in n, and of expression, which were common in L2 and . No significant methylation differences were present in parental skin cells, undifferentiated s nor -derived neural cultures not-enriched-in-n. These findings suggest the presence of molecular defects in somatic cells which manifest only upon differentiation into the n cells targeted in . The methylation profile from n, but not from controls, resembled that of neural cultures not-enriched-in-n indicating a failure to fully acquire the epigenetic identity own to healthy n in . The -associated hypermethylation was prominent in gene regulatory regions such as enhancers and was related to the and/or protein downregulation of a network of transcription factors relevant to (1, 3C1, 4A, and 2). Using a patient-specific -based n model, our study provides the first evidence that epigenetic deregulation is associated with monogenic and sporadic PD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration, Randomized crossover clinical trial in healthy volunteers

  • Barroso, Sergio|||0000-0001-7504-4794
  • Morén, Constanza|||0000-0001-6848-7407
  • González-Segura, Àlex|||0000-0002-9398-2183
  • Riba, Neus
  • Arnaiz, Joan Albert
  • Manríquez, Marcela
  • Santana, Gemina
  • Blanco Arévalo, José Luis|||0000-0003-2010-2744
  • Larousse, María
  • Loncà, Montse
  • de Lazzari, Elisa|||0000-0003-2614-6545
  • Llopis, Jaume
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Miró, Oscar|||0000-0002-7924-9751
  • Carné, Xavier
  • Gatell, José Mª|||0000-0002-4705-3244
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Martínez, Esteban|||0000-0002-6911-8846
Context Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and integrase inhibitors are supposed to be safer, but have been scarcely investigated. To avoid any interference with HIV or other antiretrovirals, we assessed markers of these toxicities in healthy adult volunteers treated with Enfuvirtide (T20) or Raltegravir (RAL). Methods Twenty-six healthy participants were randomized to T20/90mg vs. placebo (n = 12) or RAL/ 400mg vs. placebo (n = 14) every 12h in two 7-day periods separated by a 4-week washout period. Major end-points were changes in lipid profile (total cholesterol, high-density-lipoprotein (HDL)-cholesterol, low-density-lipoprotein (LDL)-cholesterol, triglycerides), insulin resistance (glucose) and mitochondrial toxicity (mitochondrial DNA content-mtDNA-in peripheral blood mononuclear cells). Renal and hepatic toxicity (creatinine, alanine transaminase (AST), alanine aminotransferase (ALT), bilirubin and total plasma proteins) and overall safety were also analysed. Effect of period, treatment, and basal measures were evaluated for each end-point. Results Neither T20-administration nor RAL-administration yielded to any statistic significant change in the markers of metabolic, mitochondrial, renal or hepatic toxicity assessed. No symptoms indicative of drug toxicity were neither found in any subject. Conclusions In absence of HIV infection, or concomitant treatment, short-term exposure to T20 or RAL in healthy adult volunteers did not lead to any indicative changes in toxicity markers thus presuming the safe profile of both drugs.